{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:14:29Z","timestamp":1793369669906,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited data are available on the risk of pancreatic adverse events among people with obesity or type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective study utilizing data from a federated research network (TriNetX). Adult people (\u2265\u200918\u00a0years) with a diagnosis of obesity (body mass index\u2009\u2265\u200930\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) or T2DM (ICD-10-CM: E11) between 2018 and 2024 were subdivided in two mutually exclusive cohorts: (1) GLP-1 RA Users; and (2) Non\u2013GLP-1 RA Users. Primary outcomes were 1-year risk of all-cause death and a composite outcome (acute pancreatitis, chronic pancreatitis). Secondary outcomes included the individual components of the composite outcome and pancreatic cancer. Cox regression analyses were employed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) before and after 1:1 propensity score matching (PSM). Sensitivity analyses stratified follow-up into early (first 6 months) and late (last 6 months) phases. Subgroup analyses were performed based on age (\u2265\u200965 or\u2009&lt;\u200965\u00a0years), sex, and the history of smoking and alcohol use, hypertriglyceridemia, cholelithiasis, heart failure, and chronic kidney disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 1,562,626 people who initiated treatment with GLP-1 RA (mean age 55.3\u2009\u00b1\u200914.0\u00a0years; 59.2% female) and 18,652,572 those who did not (mean age 50.6\u2009\u00b1\u200918.7\u00a0years; 54.5% female). Before PSM, GLP-1 RA Users were older, more frequently female, and exhibited a higher burden of endocrine, metabolic and gastrointestinal disorders. After PSM, GLP-1 RA use was associated with a substantially lower risk of all-cause death (HR 0.554, 95% CI 0.542\u20130.566), and small increased risk of the composite outcome (HR 1.062, 95% CI 1.023\u20131.102) and acute pancreatitis (HR 1.058, 95% CI 1.015\u20131.103), with no differences in chronic pancreatitis or pancreatic cancer. The excess risk of acute pancreatitis was more pronounced during the early phase of follow-up (first 6\u00a0months). Subgroup analyses showed a higher reduction in death and composite outcome among people aged\u2009&lt;\u200965\u00a0years. Additional significant interactions were observed for all-cause death in females and in people with a history of smoking, alcohol use, heart failure, chronic kidney disease, or cholelithiasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1 RA use was associated with substantially reduced all-cause death but a small increased risk of acute pancreatitis, particularly during early treatment. The survival benefit was more pronounced in younger people and those with cardiometabolic comorbidities, highlighting the need for a careful risk\u2013benefit evaluation when prescribing GLP-1 RAs in high-risk individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-025-02986-0","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:38:34Z","timestamp":1763545114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risk of all\u2013cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network"],"prefix":"10.1186","volume":"24","author":[{"given":"Enrico","family":"Tartaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Galeazzo","family":"Rigutini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Askarinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Nabrdalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"1","key":"2986_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther"},{"key":"2986_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","journal-title":"Mol Metab"},{"issue":"11","key":"2986_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"5","key":"2986_CR4","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/dom.16238","volume":"27","author":"T Bucci","year":"2025","unstructured":"Bucci T, Alam U, Fauchier G, et al. GLP-1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity. Diabetes Obes Metab. 2025;27(5):2418\u201329. https:\/\/doi.org\/10.1111\/dom.16238.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2986_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374. https:\/\/doi.org\/10.1038\/s41569-023-00849-3.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"2986_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","volume":"30","author":"HUH Ansari","year":"2024","unstructured":"Ansari HUH, Qazi SU, Sajid F, et al. Efficacy and safety of Glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pract. 2024;30(2):160\u201371. https:\/\/doi.org\/10.1016\/j.eprac.2023.11.007.","journal-title":"Endocr Pract"},{"issue":"10193","key":"2986_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"24","key":"2986_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"19","key":"2986_CR9","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"4","key":"2986_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"1","key":"2986_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38956-2","volume":"9","author":"LC Pinto","year":"2019","unstructured":"Pinto LC, Falcetta MR, Rados DV, Leit\u00e3o CB, Gross JL. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis. Sci Rep. 2019;9(1):2375. https:\/\/doi.org\/10.1038\/s41598-019-38956-2.","journal-title":"Sci Rep"},{"issue":"9","key":"2986_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","volume":"19","author":"M Monami","year":"2017","unstructured":"Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017;19(9):1233\u201341. https:\/\/doi.org\/10.1111\/dom.12926.","journal-title":"Diabetes Obes Metab"},{"key":"2986_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102661","volume":"73","author":"H Moll","year":"2024","unstructured":"Moll H, Frey E, Gerber P, et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024;73:102661. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102661.","journal-title":"EClinicalMedicine"},{"key":"2986_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002517","author":"T Weiss","year":"2022","unstructured":"Weiss T, Yang L, Carr RD, et al. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care. 2022. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002517.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"2986_CR15","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386. https:\/\/doi.org\/10.2337\/dci22-0034.","journal-title":"Diabetes Care"},{"issue":"5S","key":"2986_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Group KDIGOKDW","year":"2022","unstructured":"Group KDIGOKDW. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"issue":"38","key":"2986_CR17","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","volume":"45","author":"KC Koskinas","year":"2024","unstructured":"Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2024;45(38):4063\u201398. https:\/\/doi.org\/10.1093\/eurheartj\/ehae508.","journal-title":"Eur Heart J"},{"issue":"2","key":"2986_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/2040622315620180","volume":"7","author":"J Crane","year":"2016","unstructured":"Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016;7(2):92\u2013107. https:\/\/doi.org\/10.1177\/2040622315620180.","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"2986_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"issue":"1","key":"2986_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012940","volume":"9","author":"V Raparelli","year":"2020","unstructured":"Raparelli V, Elharram M, Moura CS, et al. Sex differences in cardiovascular effectiveness of newer glucose-lowering drugs added to metformin in type 2 diabetes mellitus. J Am Heart Assoc. 2020;9(1):e012940. https:\/\/doi.org\/10.1161\/JAHA.119.012940.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2986_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70063","volume":"17","author":"Y Yang","year":"2025","unstructured":"Yang Y, He L, Han S, et al. Sex differences in the efficacy of Glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J Diabetes. 2025;17(3):e70063. https:\/\/doi.org\/10.1111\/1753-0407.70063.","journal-title":"J Diabetes"},{"key":"2986_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Cruz LLA, Magalong JV, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100679.","journal-title":"Am J Prev Cardiol"},{"issue":"17","key":"2986_CR23","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","volume":"84","author":"BM Scirica","year":"2024","unstructured":"Scirica BM, Lincoff AM, Lingvay I, et al. The effect of Semaglutide on mortality and COVID-19-related deaths: an analysis from the SELECT trial. J Am Coll Cardiol. 2024;84(17):1632\u201342. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.007.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2986_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1056\/NEJMp1001578","volume":"362","author":"M Parks","year":"2010","unstructured":"Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide\u2013the FDA\u2019s review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774\u20137. https:\/\/doi.org\/10.1056\/NEJMp1001578.","journal-title":"N Engl J Med"},{"issue":"9","key":"2986_CR25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs\u2013FDA and EMA assessment. N Engl J Med. 2014;370(9):794\u20137. https:\/\/doi.org\/10.1056\/NEJMp1314078.","journal-title":"N Engl J Med"},{"issue":"7","key":"2986_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","volume":"173","author":"S Singh","year":"2013","unstructured":"Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2013.2720.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2986_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4158\/EP11290.OR","volume":"18","author":"HM Lando","year":"2012","unstructured":"Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012;18(4):472\u20137. https:\/\/doi.org\/10.4158\/EP11290.OR.","journal-title":"Endocr Pract"},{"issue":"2","key":"2986_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.23736\/S2724-6507.20.03219-8","volume":"48","author":"B Nreu","year":"2023","unstructured":"Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinol. 2023;48(2):206\u201313. https:\/\/doi.org\/10.23736\/S2724-6507.20.03219-8.","journal-title":"Minerva Endocrinol"},{"issue":"5","key":"2986_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70113","volume":"8","author":"J Wen","year":"2025","unstructured":"Wen J, Nadora D, Bernstein E, et al. Evaluating the rates of pancreatitis and pancreatic cancer among GLP-1 receptor agonists: a systematic review and meta-analysis of randomised controlled trials. Endocrinol, Diabetes Metab. 2025;8(5):e70113. https:\/\/doi.org\/10.1002\/edm2.70113.","journal-title":"Endocrinol, Diabetes Metab"},{"key":"2986_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030944","author":"M Ayoub","year":"2025","unstructured":"Ayoub M, Chela H, Amin N, et al. Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14030944.","journal-title":"J Clin Med"},{"issue":"5","key":"2986_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"2986_CR32","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.2337\/db11-1109","volume":"61","author":"B Gier","year":"2012","unstructured":"Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61(5):1250\u201362. https:\/\/doi.org\/10.2337\/db11-1109.","journal-title":"Diabetes"},{"issue":"7","key":"2986_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.21037\/atm.2018.02.24","volume":"6","author":"Y Saisho","year":"2018","unstructured":"Saisho Y. Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions. Ann Transl Med. 2018;6(7):131. https:\/\/doi.org\/10.21037\/atm.2018.02.24.","journal-title":"Ann Transl Med"},{"issue":"9","key":"2986_CR34","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.2337\/db09-0626","volume":"58","author":"JA Koehler","year":"2009","unstructured":"Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes. 2009;58(9):2148\u201361. https:\/\/doi.org\/10.2337\/db09-0626.","journal-title":"Diabetes"},{"issue":"4","key":"2986_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"CS Hendershot","year":"2025","unstructured":"Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatr. 2025;82(4):395\u2013405. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.4789.","journal-title":"JAMA Psychiatr"},{"issue":"1","key":"2986_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner R, Murad H, Agay N, Olmer L, Freedman LS. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024;7(1):e2350408. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50408.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2986_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ijscr.2013.04.040","volume":"4","author":"T Nakamura","year":"2013","unstructured":"Nakamura T, Masuda K, Harada S, Akioka K, Sako H. Pancreatic cancer: slow progression in the early stages. Int J Surg Case Rep. 2013;4(8):693\u20136. https:\/\/doi.org\/10.1016\/j.ijscr.2013.04.040.","journal-title":"Int J Surg Case Rep"},{"issue":"23","key":"2986_CR38","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.3748\/wjg.v27.i23.3148","volume":"27","author":"DS Umans","year":"2021","unstructured":"Umans DS, Hoogenboom SA, Sissingh NJ, Lekkerkerker SJ, Verdonk RC, van Hooft JE. Pancreatitis and pancreatic cancer: a case of the chicken or the egg. World J Gastroenterol. 2021;27(23):3148\u201357. https:\/\/doi.org\/10.3748\/wjg.v27.i23.3148.","journal-title":"World J Gastroenterol"},{"key":"2986_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.101647","volume":"64","author":"J Kirkeg\u00e5rd","year":"2020","unstructured":"Kirkeg\u00e5rd J, Gaber C, Lund JL, et al. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. Cancer Epidemiol. 2020;64:101647. https:\/\/doi.org\/10.1016\/j.canep.2019.101647.","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"2986_CR40","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.14738","volume":"24","author":"SV Deo","year":"2022","unstructured":"Deo SV, Marsia S, McAllister DA, Elgudin Y, Sattar N, Pell JP. The time-varying cardiovascular benefits of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus: evidence from large multinational trials. Diabetes Obes Metab. 2022;24(8):1607\u201316. https:\/\/doi.org\/10.1111\/dom.14738.","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"2986_CR41","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2017.10.24","volume":"5","author":"KC Ferdinand","year":"2017","unstructured":"Ferdinand KC, Mahata I. Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add? Ann Transl Med. 2017;5(23):476. https:\/\/doi.org\/10.21037\/atm.2017.10.24.","journal-title":"Ann Transl Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02986-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:38:35Z","timestamp":1763545115000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02986-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2986"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02986-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted using de-identified data from the TriNetX Research Network. All patient data are anonymized in compliance with the Health Insurance Portability and Accountability Act (HIPAA) and US federal law. No patient-level identifiers are accessible within TriNetX. In accordance with these conditions, institutional review board (IRB) approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"G.Y.H.L. has been a consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Anthos, and Daiichi-Sankyo. No fees are directly received personally. All the disclosures happened outside the submitted work. He is a National Institute for Health and Care Research (NIHR) Senior Investigator Emeritus and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalized management of atrial fibrillation and stroke (grant agreement No 101136244), and ARISTOTELES project on artificial intelligence for management of chronic long-term conditions (grant agreement No 101080189), which are all funded by the EU's Horizon Europe Research and Innovation program. G.B. reported small speaker fees from Bayer, Boehringer Ingelheim, Boston, Daiichi Sankyo, Janssen, and Sanofi outside of the submitted work. G.B. is the Principal Investigator of the ARISTOTELES project (Applying ARtificial Intelligence to define clinical trajectorieS for personalized predicTiOn and early deTEction of comorbidity and muLti-morbidity pattErnS) that received funding from the European Union within the Horizon 2020 research and innovation programme (grant no. 101080189). U.A. has received honoraria from Viatris, Gr\u00fcnenthal, Eli Lilly, Sanofi and Procter & Gamble for educational meetings, investigator-led funding from Proctor & Gamble and received sponsorship to attend educational meetings from Daiichi Sankyo and Sanofi. The other authors did not report conflicts of interest to disclose outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"438"}}